Cyprotex
Alicia Rosell-Hidalgo is an accomplished scientist currently serving as Associate Principal Scientist at Cyprotex since June 2020, where responsibilities include the management of R&D projects and commercial toxicology studies, alongside expertise in cell culture using various models. Prior to this role, Alicia completed a PhD at the University of Sussex and engaged in diverse research experiences, including high-resolution respirometry and tumor cell studies during doctoral studies from September 2017 to May 2020. Alicia also contributed to students' education as a doctoral tutor and undertook research internships at the University of Brighton and Consejo Superior de Investigaciones Científicas, focusing on cancer research and molecular biology. Alicia holds an MSc in Biochemistry and a Bachelor's degree in Biology from Universidad Complutense de Madrid.
This person is not in any offices
Cyprotex
Founded in 1999, Cyprotex (www.cyprotex.com) has grown to become an industry leader in in vitro and in silico ADME-Tox. The company, with sites in the UK and USA, was acquired by Evotec (www.evotec.com) in 2016. The Evotec Group offer expert support from early discovery through to clinical development. * High-throughput ADME screening * Customised ADME assays * In silico ADME predictive modeling * In vitro toxicology